|
|
CC1=CC2=C(C=C1Cl)N=C(S2)NC(=O)CC3=CC=CC=C3 |
Not approved |
|
CK1δ
|
Inhibits casein kinase 1 delta (CKIδ) activity
|
|
|
|
[2H]C([2H])([2H])C(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC |
Approved |
|
Melatonin receptor
|
Melatonin receptor binding
|
|
|
|
C1=CC(=O)C2=NC=CN=C2C1=O |
Not approved |
|
CLOCK-BMAL1
|
Targets BMAL1–CLOCK DNA-binding activity
|
|
|
|
C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)C(F)(F)F |
Not approved |
|
RORα
|
ROR
|
|
|
|
CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C# N |
none |
|
GSK-3α/β
|
Highly selective, ATP-competitive inhibition of GSK-3 (both α and β isoforms),
GSK‑3 Inhibition,
Selective GSK-3β Inhibition:,
inhibits glycogen synthase kinase-3β (GSK-3β)
|
|
|
|
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC |
Not approved |
|
SEROTONIN TRANSPORTER
,
PPAR gamma
,
D2R (dopamine receptor)
|
Core clock modulation,
Unknown,
Dopamine receptor binding
|
|
|
|
CCOC(CC1=CC(=CC=C1)C(=NOCC2=CC=C(C=C2)Br)C)C(=O)O |
Not approved |
|
CRY1-PER2 complex
,
CRY1
,
CRY2
|
Binds CRY1 FAD-binding,
CRY1/2 inhibitor,
Activation of CLOCK/Bmal1 mediated transcription
|
|
|
|
CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C |
Approved |
|
NMDA receptor
|
modulation of nuclear receptor signaling pathways
|
|
|
|
CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C |
Approved |
|
CLOCK-BMAL1
,
Arntl (gene)
,
BMAL1 expression (induction)
|
Bmal1,
de-repressing BMAL1,
BMAL1 expression modulation,
BMAL1 expression modulation,
Retinoic acid receptor RXR-alpha, beta, gamma binding,
Binding retinoic acid receptor alpha
|
|
|
|
CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl |
Approved |
|
CLOCK-BMAL1
,
Arntl (gene)
,
BMAL1 expression (induction)
|
Bmal1,
de-repressing BMAL1,
BMAL1 expression modulation,
BMAL1 expression modulation,
Vascular endothelial growth factor receptor 1, 2, 3,
Platelet-derived growth factor receptor alpha, beta,
Mast/stem cell growth factor receptor Kit,
Fibroblast growth factor receptor 3,
Tyrosine-protein kinase ITK/TSK,
Fibroblast growth factor 1,
SH2B adapter protein 3
|
|
|
|
C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O |
Not approved |
|
Liver X receptors
|
LXRα,
LXRβ
|
|
|
|
CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N |
Approved |
|
Adenosine A1, A2A, A2B, and A3 Receptors
|
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Inhibitor,
Adenosine receptor A1Antagonist,
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A,
Adenosine receptor A3Antagonist
|
|
|
|
CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 |
Approved |
|
CLOCK-BMAL1
,
Arntl (gene)
,
BMAL1 expression (induction)
,
Tyrosine proteine kinase ABL1
|
Bmal1,
de-repressing BMAL1,
BMAL1 expression modulation,
BMAL1 expression modulation,
"Tyrosine-protein kinase ABL1 Mast/stem cell growth factor receptor binding
|
|
|
|
CC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3 |
not approved |
|
Melatonin receptor
|
Melatonin receptor binding,
antagonist of melatonin receptors
|
|
|
|
CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O |
Approved |
|
Cannabinoid receptor
|
Cannabinoid receptor stimulation
|
|
|
|
CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3 |
Approved |
|
Melatonin receptor
|
Melatonin receptor binding
|
|
|
|
CC(=O)N1CCCC(C1)C2=CNC3=C2C=C(C=C3)OC |
Not approved |
|
Melatonin receptor
|
Melatonin receptor antagonist
|
|
|
|
CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC |
Approved |
|
T58921 Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
,
Melatonin receptor
,
MT3
,
MT1
,
MT2
,
RORα
,
Mel1C
,
CAND2
,
VDR
,
QR2
,
MMP9
,
PEPSIN
,
PP2A
,
mPTP
,
PEPT1
,
PEPT2
,
GLUT1
,
HBS
,
CaM
,
TUBULIN
,
Calreticulin
|
SIRT1,
Melatonin receptor binding,
ROR,
RORγ binding,
RORyt/RORc inhibitor,
Melatonin receptor agonist,
Antioxidant
|
|
|
|
C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O |
Approved |
|
T60529
,
MTOR (Human)
,
CLOCK-BMAL1 COMPLEX
|
SIRT1,
mTOR signaling inhibition,
Serine/threonine-protein kinase mTOR,
Altering Circadian Metabolism via the SIRT1-AMPK-PP2A Axis,
Repression of PER/CRY feedback loops via deacetylation.,
AMPK-PP2A axis suppresses mTOR, advancing circadian phase in muscle.
|
|
|
|
CC(=O)NCC1CC2=CC=CC=C2CC3=C1C=C(C=C3)OC |
not approved |
|
Melatonin receptor
|
antagonist of melatonin receptors
|
|
|
|
CC(NC([2H])([2H])C([2H])([2H])C1=CNC2=C1C=C(OC)C=C2)=O |
Approved |
|
MT1
,
MT2
|
Melatonin receptor binding
|
|
|
|
CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)I |
not approved |
|
MT1
,
MT2
|
SIRT1,
Melatonin receptor binding,
MT2 receptor antagonist,
MT1 receptor binding
|
|
|
|
CCC(=O)NC1CCC2=C(C1)C(=CC=C2)OC |
Not approved |
|
MT2
|
MT2 receptor ligand
|
|
|
|
CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC |
Aapproved |
|
Melatonin receptor
|
antagonist of melatonin receptors
|
|
|
|
CC(NCCN1C2=CC(OC)=C(Cl)C=C2N=C1OC)=O |
not approved |
|
Melatonin receptor
,
MT1
,
MT2
|
MT1 receptor binding,
MT2 receptor ligand
|
|